Review Article · e0003

Artificial intelligence in GxP-regulated pharmaceutical activities: regulatory requirements, validation, data governance and risk management

Ridvanov Ch.I. · ORCID 0009-0003-3689-1757

Ibragimova L.N. ✉ · ORCID 0000-0002-8381-5330

Citation

Ridvanov Ch.I., Ibragimova L.N. Artificial intelligence in GxP-regulated pharmaceutical activities: regulatory requirements, validation, data governance and risk management. Pharmaceutical Sciences and Health Products. 2026;1(1):e0003.

Abstract

Introduction. The digital transformation of the pharmaceutical industry, together with the development of Process Analytical Technology (PAT), continuous manufacturing, and the Pharma 4.0 concept, has created favorable conditions for the broader application of artificial intelligence (AI) and machine learning (ML) in pharmaceutical development, manufacturing, quality control, and other GxP-regulated processes. At the same time, the specific characteristics of AI/ML-based systems require the adaptation of conventional approaches to validation, data governance, risk management, human oversight, and lifecycle management of computerized systems.

Objective. To systematize current scientific and regulatory approaches to the use of artificial intelligence in GxP-regulated pharmaceutical activities and to identify the key requirements for validation, data governance, risk assessment, human oversight, and lifecycle management of AI systems.

Materials and Methods. An analytical review of the scientific literature and regulatory documents was conducted. Publications indexed in PubMed/MEDLINE were analyzed together with regulatory and guidance documents issued by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), European Commission, and International Society for Pharmaceutical Engineering (ISPE). Particular attention was given to publications and regulatory materials issued between 2020 and 2026, while earlier foundational documents related to PAT, the Pharmaceutical Quality System, Quality Risk Management, computerized systems, and continuous manufacturing were also included.

Results. The analysis demonstrated a consistent evolution of the regulatory approach to AI, from the discussion of potential applications in pharmaceutical activities toward a risk-based governance model built around a clearly defined context of use, data governance, human oversight, model performance assessment, and lifecycle management. A major milestone was the publication in January 2026 of the joint FDA-EMA Guiding Principles of Good AI Practice in Drug Development. Analysis of an FDA Warning Letter dated April 2, 2026 demonstrated the practical application of existing current Good Manufacturing Practice (CGMP) requirements to the use of AI in the preparation of regulated pharmaceutical documentation. The principal areas of AI/ML application throughout the medicinal product lifecycle were systematized, and an author-proposed three-tier risk-based classification of AI applications in the GxP environment was developed.

Conclusions. The use of artificial intelligence does not replace existing GxP requirements but expands the scope of control to include data, the model itself, its performance characteristics, changes over time, and interaction with the user. For GxP-critical AI systems, clearly defined context of use, risk-based validation, data governance, documented human oversight, performance monitoring, and change management throughout the system lifecycle are required. Integration of AI governance into the Pharmaceutical Quality System and Quality Risk Management processes is a key prerequisite for the controlled use of artificial intelligence in pharmaceutical activities.

Keywords

artificial intelligencemachine learningGxPpharmaceutical manufacturingvalidationdata governancedata integrityrisk managementFDAEMA

Article history

  1. Published

Peer-review model: Double-blind external peer review · Version: Version of Record

Supplementary materials

No separate supplementary materials.